Large Scale Biology Corporation (LSBC) is poised to enter the research grade aprotinin market during the second quarter of 2004 as a result of continued progress with the field production and bio-manufacturing program initiated at its Owensboro, Kentucky facility in April of this year. "LSBC will introduce a safe recombinant aprotinin product to the research market," said president and CEO Kevin J.Ryan. "We'll begin with research and development applications for bio-manufacturing as the first commercial phase of our progressive program."
Employing its patented Geneware technology, LSBC has conducted field trials of the recombinant aprotinin successfully since April and is now planning industrial scale production of its active pharmaceutical ingredient (API) for use in research and development. Estimates of the bio-manufacturing market for research grade aprotinin, a protease inhibitor, range up to $20 million annually.
Given global concerns and supply constraints related to bovine-sourced aprotinin, industry analysts perceive an opportunity for LSBC to exploit its unique ability to provide the market with a safer product. Geneware provides a method for producing biopharmaceuticals free of human or animal pathogens by using non-GMO, non-food plants as the production host.
Using the same patented technology, the Company has already demonstrated human safety in clinical trials of its vaccines for non-Hodgkin's lymphoma, the world's first plant-produced cancer vaccines.